98%
921
2 minutes
20
This study aims to study the role of gefitinib on patients with advanced EGFR-mutation NSCLC (Non-Small Cell Lung Cancer). Totally 115 patients with advanced EGFR-mutation NSCLC treated in our hospital were enrolled as research objects. They were randomly divided into control group (n=57) applied with cisplatin ± pemetrexed and experimental group (n=58) subject to gefitinib± cisplatin ± pemetrexed, both groups were applied with treatment for 4 cycles. Clinical efficacy: The disease control rate (DCR) was 72.41% in the experimental group, which was higher than that of the control group (54.39%, p<0.05); Serum CEA, CYFRA21-1, MMP-9 levels: after 2 and 4 cycles of treatment, serum CEA, CYFRA21-1, and MMP-9 levels were lower in the experimental group (p<0.05); Immune function: after 2 and 4 cycles of treatment, Th1 cells and Th1/Th2 cell levels were higher in the experimental group, while Th2 cell level was higher in the control group (p<0.05); Angiogenesis related indicators: the levels of VEGF, HIF-1α and sCD105 were lower in the experimental group after 2 and 4 cycles of treatment (p<0.05); (5) Adverse reactions: After 2 and 4 cycles of treatment, the levels of VEGF, HIF-1α, and sCD105 were lower in the experimental group (p<0.05). The application of gefitinib in patients with advanced EGFR-mutation NSCLC can help down-regulate CEA, CYFRA21-1, and MMP-9 levels, inhibit angiopoiesis, enhance immune function, and increase disease control rate.
Download full-text PDF |
Source |
---|
Int J Epidemiol
August 2025
Department of Biostatistics and Informatics, University of Colorado, Aurora, CO, United States.
Background: Existing longitudinal cohort study data and associated biospecimen libraries provide abundant opportunities to efficiently examine new hypotheses through retrospective specimen testing. Outcome-dependent sampling (ODS) methods offer a powerful alternative to random sampling when testing all available specimens is not feasible or biospecimen preservation is desired. For repeated binary outcomes, a common ODS approach is to extend the case-control framework to the longitudinal setting.
View Article and Find Full Text PDFJMIR Ment Health
September 2025
National Institute of Health and Care Research MindTech HealthTech Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Background: Cross-sector collaboration is increasingly recognized as essential for addressing complex health challenges, including those in mental health. Industry-academic partnerships play a vital role in advancing research and developing health solutions, yet differing priorities and perspectives can make collaboration complex.
Objective: This study aimed to identify key principles to support effective industry-academic partnerships, from the perspective of industry partners, and develop this into actionable guidance, which can be applied across sectors.
Neuro Endocrinol Lett
September 2025
Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Background: Major depressive disorder (MDD) is associated with neuro-immune - metabolic - oxidative (NIMETOX) pathways.
Aims: To examine the connections among NIMETOX pathways in outpatient MDD (OMDD) with and without metabolic syndrome (MetS); and to determine the prevalence of NIMETOX aberrations in a cohort of OMDD patients.
Methods: We included 67 healthy controls and 66 OMDD patients and we assessed various NIMETOX pathways.
Neuro Endocrinol Lett
September 2025
Department of Pediatric Neurology, Cukurova University Faculty of Medicine, Adana, Turkey.
Objective: It is important to raise awareness of the nutritional problems that can be overlooked during the follow-up visits with children who suffer from neuromuscular diseases, as these dietary differences may lead to additional neurological and systemic problems and impair the quality of life of the patient. The aim of this study was to evaluate the nutritional status of children with neuromuscular disorders and to prevent possible complications by recognizing possible nutritional problems in advance.
Methods: Patients who applied to the outpatient clinic at Cukurova University, Faculty of Medicine, Department of Pediatric Neurology beginning in April 2022 with a neuromuscular disorder diagnosis were followed up with and were included in the study.
Ann Am Thorac Soc
September 2025
Hadassah Medical Center, Pediatric Pulmonology Unit and Cystic Fibrosis Center, Jerusalem, Jerusalem, Israel.
Background Although advances in care have improved cystic fibrosis (CF) outcomes in higher-income countries (HICs), the situation remains alarming in lower-income countries (LICs). Methods People with CF (pwCF) enrolled in the European Cystic Fibrosis Society Patient Registry (ECFSPR) and carrying at least one F508del variant allele were evaluated in 2017 and in 2022 for predicted percent forced expiratory volume (ppFEV1), underweight status, and chronic Pseudomonas aeruginosa (Pa) infection, according to the gross national income (GNI) per capita divided into three terciles (low-income countries, LICs; middle-income countries, MICs; and high-income countries, HICs). Survival was evaluated in the periods 2013-2017 and 2018-2022.
View Article and Find Full Text PDF